Volume surge · IONS · Healthcare

Ionis Pharmaceuticals Inc (IONS) takes a 28.8% weekly hit

Heavy turnover points to broad participation in the selloff as the biotechnology stock remains under technical pressure.

Ionis Pharmaceuticals Inc
Latest58.25 USD
1W move-28.8%
Volume3.5x
TrendInactive
Biotechnology lab and financial chart visual representing Ionis Pharmaceuticals market activity.

Market update

What happened

Ionis Pharmaceuticals Inc (IONS) closed at $58.25 for the week ended July 10, extending losses across the short and medium term. The stock is down -20.5% over four weeks and -23.1% over twelve weeks.

The weekly price path over 52 weeks shows a damaged setup rather than live intraday action. The trend signal is inactive, Market Dynamics remains weak at 0.35, and Relative Strength is deeply negative at -28.9.

Continue your research

Explore IONS across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.Insider transactionsSee reported purchases and sales by company directors and executives.

Biotechnology coverage

Evidence context